ADC Therapeutics SA (ADCT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Core Insights - ADC Therapeutics is focused on expanding the use of its approved product ZYNLONTA in earlier lines of DLBCL and indolent lymphomas, with significant accomplishments expected in 2025 [2] - The company aims to derisk its portfolio of trials for ZYNLONTA and strengthen its capital position through restructuring and equity raises [2] - Key data disclosures for multiple studies are anticipated in 2025, with expected growth starting in 2027 and continuing into 2028 and beyond [3] Company Overview - ADC Therapeutics operates in the ADC (Antibody-Drug Conjugate) space and has an approved product, ZYNLONTA, which is a CD19 directed ADC using a PBD-based warhead [3] - The company is preparing for final data disclosures in 2025, which are crucial for derisking its clinical trials [3] - The anticipated approval and compendia inclusion for multiple new uses of ZYNLONTA are expected to drive growth from 2027 onwards [3]